Purpose: The purpose of the study is to determine whether initiatives to improve the safety of opioid prescribing decreased injuries in people using chronic opioid therapy (COT).
Many people now use opioids chronically for noncancer pain. In 2012, 7 .3% of US adults with Medicare drug coverage received 90 or more days' supply of opioids. 1 There is growing concern about possible harms of prescription opioid use including injuries, overdose, and addiction. 2 Many organizations have made efforts to reduce those risks. In 2007, Washington State released a guideline aimed at reducing high-dose opioid prescribing, which became state law in 2010. In 2016, the US Centers for Disease Control released guidelines for opioid prescribing for chronic pain 3 and the Surgeon General sent a letter to US physicians urging more cautious prescribing. 4 One major challenge is that we do not know which practices are effective for reducing opioid-related risks, and few studies have examined whether specific initiatives have improved health outcomes. 5 In 2007, one health care system, Group Health, launched an effort within its own clinics (the "integrated group practice" (IGP)) to improve the safety of chronic opioid therapy (COT). GH's initiatives 6, 7 (described in more detail below) included physician education, dose reduction, risk stratification of patients, and increased monitoring. In regions where GH did not operate clinics, members received care from contracted providers ("contracted care") not exposed to GH's initiatives, providing a natural comparison group. GH's initiatives led to much greater use of opioid care plans and urine drug screening 7, 8 and substantial reductions in opioid daily dose. 6 After the initiatives, 85% of IGP patients had care plans, 7, 8 and urine drug testing increased from 7% to 50%. 7, 8 However, these initiatives did not decrease the risk of prescription opioid use disorder 9 or motor vehicle collisions (MVCs). 10 GH's opioid initiatives could have impacted different outcomes differently. Thus, there is a need to examine other clinical outcomes.
Prescription opioid use is associated with increased risk of falls, fractures, or other injuries. [11] [12] [13] [14] [15] [16] [17] To our knowledge, no studies have examined whether opioid risk reduction initiatives reduce injury risk. Thus, we sought to determine whether GH's initiatives had an impact on rates of medically attended injury. We hypothesized that (1) injury rates would decrease among COT patients in the IGP after risk reduction initiatives began, (2) the decrease would be greater in the IGP than in contracted care, and (3) reductions would be greater in people age 65 and older and those using sedative hypnotics, who are at higher risk for injury.
2 | METHODS
| Study overview
We carried out interrupted time series analyses examining injury rates among people using COT within GH, an integrated healthcare delivery system. In 2017, GH was acquired by Kaiser Permanente, but we refer to it in this paper as GH. Using electronic health data, we examined changes in injury rates over time adjusting for other risk factors. Study procedures were approved by GH's Human Subjects Review Committee, with a waiver of consent.
| Setting
GH (now Kaiser Permanente Washington) provides health care and insurance coverage to about 700 000 people in the Northwest United
States. Members are insured through commercial plans, Medicare, and
Medicaid and are broadly representative of the region. About twothirds receive care within the IGP, while others receive their care from contracted providers (usually because they live in a geographic region where GH does not operate facilities). Because GH does not own hospitals, IGP members receive inpatient care at contracted hospitals.
They may also receive care at community emergency departments (EDs). Contracted care patients typically receive all care from non-GH clinicians at contracted facilities. For both populations, GH receives detailed information about outside care (including diagnosis and procedure codes) through insurance claims, ensuring complete data capture.
| Population
We identified GH members age 18 years or older enrolled in the health plan for at least 12 months who used COT between 2006 and 2014. COT was defined as receiving 70 or more days' supply of opioids in a calendar quarter (90 days). Opioid prescription fills were identified from automated pharmacy data. On a survey, 96% of patients in both the IGP and contracted care reported receiving all of their prescription opioids in the prior year through their GH insurance. Each quarter in which a person received COT constituted an "eligibility quarter."
We excluded people who had a cancer diagnosis recorded at more than one encounter or were receiving hospice care. To ensure that we were identifying new injuries, we excluded people with injury diagnosis codes during the eligibility quarter or the prior 9 months.
KEY POINTS
• There is growing public concern about the possible harms of prescription opioid use including falls and injuries.
• There is little evidence regarding which policies or clinical practices are effective in reducing opioidrelated risks for patients on chronic opioid therapy (COT).
• We examined whether initiatives at one healthcare system that substantially reduced opioid doses and increased patient monitoring led to lower rates of injuries including fractures and concussions among COT patients.
• We found that these initiatives did not lower injury rates.
• New approaches are needed to reduce the risks and harms of chronic opioid therapy. GH implemented revised guidelines with more requirements for monitoring, risk stratification, care plans, and urine drug tests. We refer to this as the "risk stratification and monitoring" period. We previously reported that this guideline change led to dramatic increases in care plans 7 and urine drug screening. 8 The current analyses focus on three 
| Outcomes
We measured medically attended fractures, concussions, and other head for each algorithm, resolving differences through discussion. Our initial algorithms had low positive predictive value (PPV) for dislocations and high PPV for other injury types. Attempts to improve the dislocation algorithm were not successful, and so, this outcome was dropped.
For fractures, we required either (1) at least one inpatient or ED visit with a fracture code or (2) two outpatient or urgent care visits with codes involving the same body region within a 6-week period and an X-ray within 7 days of the first diagnosis. The date of the first visit was taken as the date of fracture. Chart reviews showed that most patients with rib fractures had only one visit, so for rib fractures, we allowed a single visit to qualify. We defined a concussion as present if there was at least one visit in any setting with a relevant diagnosis code.
The same definition was used for other head injuries, which included cerebral lacerations or contusions and subarachnoid or subdural hemorrhages. See Appendices A and B for codes. PPVs were as follows:
for fractures, 90% (95% CI, 67%-99%); for concussions, 86% (95% CI, 64%-97%); and for other head injuries, 90% (95% CI, 67%-99%).
For every eligibility quarter, we determined whether there was an injury in the following quarter (the "outcome quarter"). We defined a "washout" period of 18 months after each injury during which we assumed that additional codes represented continuing care rather than a new injury. People could contribute more than outcome quarter with an injury.
| Covariates
From electronic health data, we identified the following covariates: where long-term use is probably more important, we defined exposure as receiving two or more fills in the past 3 years, while for oral glucocorticoids, we required five or more fills.
We estimated daily opioid dose as in prior work. 10, 18, 19 First, we identified all opioid prescription fills overlapping the eligibility quarter.
For each fill, we multiplied the number of pills by the strength and then applied a conversion factor to calculate MEDs. We then summed up the available opioid amount within that quarter, including prescriptions that partially overlapped the quarter on a pro-rated basis, and divided by 90 days to get the estimated daily dose.
The following comorbid illnesses were defined from diagnosis codes during the 3 years prior to the outcome quarter: alcohol abuse or dependence, nonopioid drug abuse or dependence, sleep disorders, congestive heart failure (CHF), ischemic heart disease, dementia, anxiety disorders, diabetes mellitus (DM), depression, and history of stroke. We defined depression and dementia as present if either diagnosis codes or medication fills were present. We calculated the Romano-Charlson comorbidity index for the 12-month period prior to the outcome quarter. 20 
| Statistical analysis
We described population characteristics in different time periods and for the IGP vs contracted care, calculating means and standard deviations for continuous variables and proportions for categorical variables.
We used generalized estimating equations (GEE) with an independence working correlation matrix to estimate a modified Poisson regression model for a binary outcome. 21 We estimated adjusted relative risks (RR) and 95% confidence intervals (CI) representing the change per year in rate of injury among COT users in the IGP and contracted care in each time period. Robust standard errors were estimated with the sandwich estimator to account for the misspecified variance structure and within-person correlation over time. 21, 22 The model included main effects for the setting (IGP or contracted care) and calendar time specified using linear splines, 23 with knots at the transitions between the three time periods. Models included interactions between the setting and time and adjusted for age, gender, residence, season, comorbid illnesses, and other medications. We plotted unadjusted quarterly injury rates and curves showing "standardized"
estimates from the regression model. The latter estimates are standardized to a common distribution of patient characteristics, those observed in the IGP for the entire study period.
In subgroup analyses, we stratified by use of sedative-hypnotic medications and by age. In secondary analyses, we examined the relationship between daily opioid dose and injury risk to shed light on how dose changes might be expected to impact injury rates. These analyses included all patients from the primary analysis but included all followup time, including quarters in which they were no longer using COT.
By including outcome quarters after COT discontinuation, we identified a reference group that should be more similar to current users than people who had never used opioids, thus reducing confounding.
We modeled the association between dose and injury risk using natural cubic splines and indicators for current COT usage in a modified
Poisson regression model, adjusting for covariates and accounting for time trends using linear splines.
We performed all analyses using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC) and R, version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). Characteristics of each person during his or her first COT eligibility quarter during the entire study period. Most covariates were defined as present based on the presence of a diagnosis or prescription fill during the 3 years prior to the end of the eligibility quarter. Exceptions are identified using footnotes.
b Depression and dementia were defined as present based on either receipt of a diagnosis or a fill for an antidepressant or dementia medication.
c Use of these medications was defined based on use in the eligibility quarter only.
d Defined as receiving two or more prescription fills in the 3 years prior to the end of the eligibility quarter.
e Defined as receiving five or more prescription fills in the 3 years prior to the end of the eligibility quarter.
During the study period, there were 21 853 eligible people receiving COT in the IGP and 8260 in contracted care. Table 1 shows characteristics of the study population. The mean age was 55.9 years, and 63% were female. In the baseline period, the mean opioid daily dose (Table 2 ). In the IGP, during the dose reduction initiative, the estimated RR for injury was 1.01 (95% CI 0.95-1.07), while in contracted care (not exposed to GH initiatives), the RR was 1.13
(1.00-1.28). These RRs were not significantly different (P = 0.095).
During the risk stratification and monitoring period, the IGP RR Injury trends did not differ by age group. In the IGP, during the dose reduction period, injury risk declined slightly among people using sedative hypnotics (RR 0.91, 95% CI 0.93-1.00) while increasing slightly among nonusers (RR 1.08, 95% CI 1.00-1.17; P < 0.01 for a difference between these groups). There was no interaction with sedative hypnotic use during the other time periods. 
| DISCUSSION
We examined injury rates among people using COT during a time period when major risk reduction initiatives were implemented and there were substantial decreases in opioid dose 6 and increases in patient monitoring. 7, 8 We found that injury rates did not decrease but instead remained similar to rates in a care setting not affected by these initiatives. There may have been a small reduction in injury rates among people using both opioids and sedative hypnotics, but this finding was modest.
To our knowledge, this is the first study to examine the impact of opioid risk reduction initiatives on injury rates. Our findings may seem surprising given that other studies have linked opioid use with falls and injuries. [11] [12] [13] [14] [15] [16] [17] There are several possible explanations. First, these studies did not examine COT but rather "current use" of opioids, which may have predominantly represented short-term use. Some studies have suggested that injury risk is highest with initiation of opioids and diminishes rapidly with continued use. 14, 15, 24 Patients using opioids chronically may develop tolerance, reducing side effects such as sedation that could cause falls. If this is true, then lowering doses in patients on stable regimens would not be expected to prevent injuries. Second, the relationship of opioid dose to injury risk is unclear.
We observed that at doses greater than 20 mg/day, injury risk was not strongly related to dose. Although daily opioid dose went down in the IGP after GH's initiatives, 6 perhaps this reduction was not large enough to reduce injury risk.
The failure of GH's initiatives to reduce injury rates raises the question of what interventions might be more effective. Figure 2 suggests that reducing daily doses below 20 mg in MED might yield benefits. Many COT patients also take benzodiazepines and muscle relaxants, which may increase the risk of falls and overdose. Stronger efforts to discourage concomitant use of these medications, including through educating patients, may have potential. Since fall risk is highest at the time of opioid initiation, 14, 15, 24 efforts targeting new use (including short-term use) may be more effective than focusing on chronic use. For instance, teaching providers to assess fall risk and discuss this risk with patients when weighing whether to start an opioid could be helpful.
FIGURE 1
Injury rates over time in people using chronic opioid therapy within the integrated group practice (IGP) and contracted care. Triangles represent actual injury rates in the IGP population each quarter and squares, rates in the contracted care population. The solid curve represents a smoothed estimate of the injury rate in the IGP over time and the dashed curve an estimate of the rate in contracted care, adjusting for covariates and standardizing to account for differences in the distribution of these characteristics between the two populations and between time periods
Strengths of this study include rich electronic health data for a well-defined population, as well as the use of a comparator population not exposed to risk reduction initiatives. Our outcome measure was based on patient input. Because GH provides insurance coverage as well as health care, we have comprehensive data capture including for injuries treated outside of our health care system. Our small validation study showed that our outcome measures had high PPV. The interrupted time series approach accounts for possible temporal trends in the outcome that are not related to the intervention being studied. In situations where a randomized trial is not practical or ethical, studies of "natural experiments" such as this can provide strong evidence about the effects of policy changes. 25, 26 The study has limitations. We do not have information about
interventions the contracted care physicians may have been exposed to. Because there was no randomization, it is possible that patients exposed to the initiatives differed from those who were not exposed in ways we could not measure. Our measures of alcohol and drug use disorders may underestimate their prevalence. We cannot determine whether patients actually took the medications dispensed to them or used additional opioids (including street drugs) from other sources. If patients paid out of pocket for opioids, we would lack information about those prescriptions. However, 96% of COT patients reported filling all of their opioid prescriptions using their GH coverage. There could be misclassification of injury outcomes, and we were not able to measure all injuries that are meaningful to patients. Medically attended injuries were not common, and the contracted care population was fairly small, leading to variability in the injury rate from quarter to quarter. Thus, injury trends in the contracted care population were estimated with less precision than in the IGP, which could have reduced our ability to detect differences.
In conclusion, extensive efforts within one health care system to reduce risks associated with COT did not reduce injuries. In other work, we have found no reduction in MVCs 10 or risk of prescription opioid disorder. 9 These findings suggest that despite considerable investment of resources, the current approach is not improving important clinical outcomes. It is time to rethink our assumptions about what it will take to reduce the risks of prescription opioids and consider alternative strategies.
Investigator of grants to Group Health Research Institute (now Kaiser
Permanente Washington Health Research Institute or KPWHRI) from Pfizer Inc. that concerned opioids. These grants also supported work on opioids by SMS, KS, and RLW. Pfizer Inc. also supported work on a different phase of this evaluation that was completed 2 years ago.
MVK and SMS are coinvestigators on grants to KPWHRI from Syneos FIGURE 2 Injury risk in relation to average daily dose of prescription opioids. The curve shows relative risk of injury for people using COT according to their daily opioid dose (in milligrams of morphine equivalent doses, or MEDs). Opioid dose is modeled using natural cubic splines and indicators for current COT usage, and the referent group is people who previously used COT but have discontinued use (ie, now using 0 mg MED daily)
